Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM-101 plus stereotactic radiotherapy for locally advanced pancreatic cancer
NL-OMON49825Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IMM-101 in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by Erasmus MC. Primary endpoints: Safety in phase I and One-year progression-free survival improvement. Started Oct 2019; status: recruiting.
02
Drugs
IMM-101
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON49825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49825.